

#1 y

Attorney Docket No. T9479.B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: RAYMOND F. GESTELAND)
et al.)
TITLE: FINDING ACTIVE)
ANTISENSE)
OLIGONUCLEOTIDES USING)
ARTIFICIAL NEURAL)
NETWORKS)
SERIAL NO.: 10/050,888)
FILED: January 14, 2002)
EXAMINER: _____)
ART UNIT: 1623)

SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R.
§ 1.97

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). Applicant respectfully invokes the Patent Office's obligation under 37 C.F.R. § 1.97 to consider these references and make them of record in the above-captioned application. While no representation is made that

Certificate of Deposit Under 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on the 29th day of April, 2002.

Alan J. Howarth
Attorney Registration No. 36,553

any of these references may be "prior art" within the meaning of that term under 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.


Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that the references listed, together with any other references which may have been previously cited by or submitted to the Office, are the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

In accordance with 37 C.F.R. §§ 1.97 and 1.98, a copy of each listed reference (or relevant portion thereof) which was not previously submitted to, or cited by, the Patent Office is also enclosed.

Please charge any additional fees or credit any overpayment to
Deposit Account No. 50-1977.

DATED this 22nd day of April, 2002.

Respectfully submitted,




Alan J. Howarth
Attorney Registration No. 36,553

CLAYTON, HOWARTH & CANNON, P.C.
P.O. Box 1909
Sandy, UT 84091
Telephone: (801) 255-5335
Facsimile: (801) 255-5338

AJH/kd

S:\CHC Files\T 9--\T94--\T9479\B\Supp IDS.wpd

(4)

PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. T9479.B		SERIAL NO. 10/050,888	
 LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT Raymond F. Gesteland et al.			
				FILING DATE January 14, 2002		GROUP 1623	
U.S. PATENT DOCUMENTS							
EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	<u>TRANSLATION</u> YES NO
	AG						
OTHER PRIOR ART (Including Author, Title, Volume and/or Name of Publication, Relevant Pages and Date [as available])							
	AH		Christian Lefebvre d'Hellencourt, et al., Inhibition of human TNF α and LT in cell-free extracts and in cell culture by antisense oligonucleotides; Biochimica et Biophysica Acta, 1996, Vol. 1317, pp. 168-174. ✓				
	AI		Kalim U. Mir et al., Determining the influence of structure on hybridization using oligonucleotide arrays; Nature Biotechnology, 1999, Vol. 17, pp. 788-792. ✓				
	AJ		Ming-Yi Chiang, et al., Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms; Journal of Biological Chemistry, 1991, Vol. 266, No. 27, pp. 18162-18171. ✓				
	AK		C. Frank Bennett, et al., Inhibition of Endothelial Cell Adhesion Molecule Expression with Antisense Oligonucleotides; Journal of Immunology, 1994, Vol. 152, pp. 3530-3540. ✓				
	AL		Che-Hung Lee, et al., Antisense Gene Suppression Against Human ICAM-1, ELAM-1, and VCAM-1 in Cultured Human Umbilical Vein Endothelial Cells; SHOCK, 1995, Vol. 4, No. 1, pp. 1-10. ✓				
	AM		Loren Miraglia, et al., Inhibition of Interleukin-1 Type I Receptor Expression in Human Cell-Lines by an Antisense Phosphorothioate Oligodeoxynucleotide, Int. J. Immunopharmac., 1996, Vol. 18, No. 4, pp. 227-240. ✓				
	AN		Siew Peng Ho, et al., Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries, Nature Biotechnology, 1998, Vol. 16, pp. 59-63. ✓				
	AO		Guang-chou Tu, et al., Tetranucleotide GGG Motif in Primary RNA Transcripts, Journal of Biological Chemistry, 1998, Vol. 273, No. 39, pp. 25125-35131. ✓				
	AP		S. Patrick Walton, et al., Prediction of Antisense Oligonucleotide Binding Affinity to a Structured RNA Target, Biotechnol Bioeng, 1999, Vol. 65, pp. 1-9. ✓				
	AQ		Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 1998, Vol. 23, pp. 45-50. ✓				
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							